Research analysts at Leerink Swann upped their price target on shares of Amicus Therapeutics (NASDAQ:FOLD) from $2.50 to $3.00 in a report released on Tuesday, Analyst Ratings Network.com reports. Leerink Swann’s target price suggests a potential upside of 19.52% from the stock’s previous close.Amicus Therapeutics, Inc. (NASDAQ:FOLD) stock opened at $2.42 in last session, and closed at $2.29, while the day range of stock is $2.29 – $2.44. The stock showed a negative weekly performance of -9.13%.
Cara Therapeutics Inc (NASDAQ:CARA) is now covered by analysts at Canaccord Genuity. They set a “buy” rating and a $25.00 price target on the stock. Cara Therapeutics Inc (NASDAQ:CARA) stock opened at $21.79, in last session and closed at $20.00, by losing -5.62%. The 52 week range of the stock is $10.40 – $23.25. Company’s market capitalization is $436.85 million.
PTC Therapeutics, Inc. (NASDAQ:PTCT) posted its quarterly earnings results on Thursday. The company reported ($0.75) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.57) by $0.18,AnalystRatingsNetwork reports. PTC Therapeutics, Inc. (NASDAQ:PTCT) stock decreased -7.13% and finished the last session at $31.00. The EPS of the stock remained -12.81. Company’s market capitalization is $911.50 million.
Heat Biologics Inc (NASDAQ:HTBX) has started dosing patients in its Phase I/II bladder cancer clinical trial of its investigational biologic product candidate, HS-410. Heat Biologics Inc (NASDAQ:HTBX) stock opened the session at $6.98, and closed the session at $6.09. The 52 week range of the stock remained $5.95 – $15.29 and the day range was $5.95 – $6.98.